VXA Placebo Tablets

OTHER2 trials

Sponsors

Vaxart

Conditions

Norovirus GastroenteritisRespiratory Syncytial Virus (RSV)

Phase 1

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

CompletedNCT02830932

VaxartRespiratory Syncytial Virus (RSV)

Start: 2016-06-22End: 2017-09-20Updated: 2018-08-16

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

CompletedNCT02868073

VaxartNorovirus Gastroenteritis

Start: 2016-07-29End: 2017-10-01Updated: 2018-05-31

Related Papers

Oral immunization of a rAd vector expressing norovirus VP1 elicits a potent mucosal immune response without an increase in anti-vector immunity

International Journal of Infectious Diseases2018-07-27

Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.

2018-07-1299 citations